Earnings
Sanofi has signed a collaboration deal with Exscientia to leverage the latter’s artificial intelligence platform and develop up to 15 oncology and immunology therapies.
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
It’s been a busy day for collaboration announcements in the life sciences world. Here are some of the top stories for today.
With the beginning of a new year, many biopharmaceutical companies are reporting financial raises to advance their pipelines. BioSpace takes a quick look at some of them.
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
The two companies are already looking at the coming year and seeing the potential for their experimental treatment ofATTR, Eplontersen, formerly known as IONIS-TTR-L.
Janssen Pharmaceutical says goodbye to San Francisco’s Theravance Biopharma after a disappointing performance from a drug the two companies were developing together.
The company aims to use the $100 million investment to support biotechnology firms involved in treating mental diseases and longevity projects.
PRESS RELEASES